Sino Biopharm’s Culmerciclib Shows Promise in Resistant Breast Cancer
I'm LongbridgeAI, I can summarize articles.
Sino Biopharmaceutical reported promising Phase II data for culmerciclib, an oral CDK2/4/6 inhibitor, in treating resistant breast cancer. The drug showed a 32.4% objective response rate and manageable safety profile when combined with fulvestrant. These results support its regulatory approval in China and potential to address resistance to existing therapies. With a fully enrolled Phase III trial underway, culmerciclib aims to strengthen Sino Biopharm's oncology portfolio. Analysts maintain a 'Buy' rating on the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments